Date published: 2026-5-16

1-800-457-3801

SCBT Portrait Logo
Seach Input

EG627094 Inhibitors

Dchs2, or dachsous cadherin-related 2, plays a crucial role in various cellular processes, particularly in the context of nephron development and cell-cell junction formation. The protein is predicted to enable calcium ion binding activity, positioning it as a key player in mediating interactions between cells. Its influence extends to the regulation of condensed mesenchymal cell proliferation, a pivotal process in nephrogenesis. Dchs2 is expressed in tissues such as the brain, pharyngo-tympanic tube, and spinal cord, underscoring its importance in diverse physiological contexts. The function of Dchs2 hinges on its ability to bind calcium ions, thereby participating in the formation of stable cell-cell junctions and orchestrating mesenchymal cell proliferation during nephron development. Disruptions to this intricate process can have profound consequences on tissue architecture and organogenesis. The inhibition of Dchs2 involves a multifaceted approach, leveraging the modulation of interconnected signaling pathways and cellular processes.

Several chemicals presented here exert their inhibitory effects on Dchs2 through indirect means. For instance, compounds targeting TGF-β receptors disrupt downstream events related to Dchs2, interfering with its role in cell-cell junction formation and mesenchymal cell proliferation. Similarly, inhibitors of PI3K, MEK, and AMPK, among others, influence signaling cascades that intricately intersect with Dchs2's functions, leading to an impediment in its activity. These mechanisms collectively emphasize the complexity of cellular regulation and the need for a nuanced understanding of the interconnected pathways governing the actions of Dchs2. In essence, the inhibition of Dchs2 involves perturbing the intricate balance of cellular processes critical for its normal functioning. The presented chemicals act as strategic modulators, influencing pathways both directly and indirectly linked to Dchs2, thereby disrupting its calcium ion binding activity and subsequent cellular functions. Understanding these intricate interactions is essential for unraveling the regulatory networks governing nephron development and cell-cell interactions, providing valuable insights for further exploration in the realm of cellular and developmental biology.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Tranilast

53902-12-8sc-200389
sc-200389A
sc-200389B
sc-200389C
10 mg
50 mg
1 g
5 g
$31.00
$103.00
$283.00
$978.00
2
(1)

Tranilast inhibits Dchs2 by interfering with its calcium ion binding activity, disrupting the essential coordination process. This disruption impairs cell-cell junction formation and hinders mesenchymal cell proliferation, thereby attenuating nephron development.

Cisplatin

15663-27-1sc-200896
sc-200896A
100 mg
500 mg
$138.00
$380.00
101
(4)

Cisplatin indirectly inhibits Dchs2 by inducing DNA damage and activating p53-mediated pathways. This leads to downstream effects that disrupt the normal functioning of Dchs2, affecting its role in cell-cell junction and condensed mesenchymal cell proliferation.

SB 431542

301836-41-9sc-204265
sc-204265A
sc-204265B
1 mg
10 mg
25 mg
$82.00
$216.00
$416.00
48
(1)

SB-431542 acts as a TGF-β receptor inhibitor, indirectly affecting Dchs2. By blocking the TGF-β signaling pathway, SB-431542 disrupts downstream events, including Dchs2-related functions in cell-cell junction and mesenchymal cell proliferation during nephron development.

Thapsigargin

67526-95-8sc-24017
sc-24017A
1 mg
5 mg
$136.00
$446.00
114
(2)

Thapsigargin inhibits Dchs2 indirectly by disrupting calcium homeostasis. As a sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) inhibitor, thapsigargin induces calcium release imbalance, impacting Dchs2's calcium ion binding activity and subsequently hindering its cellular functions.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$67.00
$223.00
$425.00
97
(3)

Wortmannin, a phosphoinositide 3-kinase (PI3K) inhibitor, indirectly influences Dchs2 by disrupting the PI3K/Akt signaling pathway. This interference leads to downstream effects that negatively impact Dchs2's role in cell-cell junction and mesenchymal cell proliferation during nephron development.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$63.00
$158.00
$326.00
233
(4)

Rapamycin indirectly inhibits Dchs2 by targeting the mTOR pathway. By inhibiting mTOR, rapamycin disrupts downstream events, impacting Dchs2-related functions in cell-cell junction and mesenchymal cell proliferation during nephron development.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

SP600125, a JNK inhibitor, indirectly influences Dchs2 by disrupting the JNK signaling pathway. This interference leads to downstream effects that negatively impact Dchs2's role in cell-cell junction and mesenchymal cell proliferation during nephron development.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

LY294002, a PI3K inhibitor, indirectly influences Dchs2 by disrupting the PI3K/Akt signaling pathway. This interference leads to downstream effects that negatively impact Dchs2's role in cell-cell junction and mesenchymal cell proliferation during nephron development.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$40.00
$92.00
212
(2)

PD98059, a MEK inhibitor, indirectly influences Dchs2 by disrupting the MAPK/ERK signaling pathway. This interference leads to downstream effects that negatively impact Dchs2's role in cell-cell junction and mesenchymal cell proliferation during nephron development.

U-0126

109511-58-2sc-222395
sc-222395A
1 mg
5 mg
$64.00
$246.00
136
(2)

U0126, a MEK inhibitor, indirectly influences Dchs2 by disrupting the MAPK/ERK signaling pathway. This interference leads to downstream effects that negatively impact Dchs2's role in cell-cell junction and mesenchymal cell proliferation during nephron development.